Another example is the approval of the radiotherapeutic [177Lu]Lu-PSMA-617 (PluvictoTM) in 2022 for prostate cancer (targeting prostate specific membrane antigen, PSMA), following the approval of its imaging probe [68Ga]Ga-PSMA-11 (Locametz®) in 2021 [8,9]. This evidence concerns the gene FOLH1 and prostate carcinoma.